ArticleCancer management and research2025
Hypofractionated Radiotherapy for Prostate Cancer: A Comparative Study of Clinical Outcomes and Dosimetry Between Proton and Photon Therapy.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypofractionated radiation therapy (HFRT) is increasingly accepted for prostate cancer. This prospective study compared clinical outcomes, early prostate-specific antigen (PSA) dynamics, and dosimetry between proton and photon HFRT for high-risk prostate cancer. Methods: A total of 118 patients with high-risk prostate cancer were treated with HFRT (70Gy in 28 fractions) between 2022-2024, receiving either intensity-modulated proton therapy (IMPT, n = 36) or photon therapy (VMAT, n = 82). All patients received long-term androgen deprivation therapy (ADT). Primary endpoints included biochemical control, PSA nadir at 6 months post-treatment, and genitourinary (GU) and gastrointestinal (GI) toxicities. Dosimetric comparisons were performed in silico. Results: While biochemical control rates were comparable, a significantly higher proportion of patients receiving proton therapy achieved a PSA nadir <0.1 ng/mL within 6 months. Proton therapy was associated with reduced GU toxicity compared to photon therapy, based on assessments from both physicians and patients. Dosimetric analysis confirmed that proton therapy provided excellent target coverage with superior organ-at risk (bladder and rectum) sparing. We further identified dosimetric parameter to determine the cuff-off value for GU events. The data revealed the percentage volume of bladder receiving ≥90% prescribed dose (V90%) ≥11% has the predictive value for the development of grade ≥2 genitourinary toxicity. Conclusion: Two-year biochemical control was comparable between proton- and photon- based HFRT in high-risk prostate cancer. Proton therapy demonstrated improved early PSA kinetics and reduced GU toxicity, supported by favorable dosimetric profiles. The identification of bladder V90% <11% as a planning constraint may guide treatment optimization. Further studies with longer follow-up are warranted to validate these benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.